Hypertrophic cardiomyopathy
Conditions
Interventions
Group 1:percutaneous endocardial septal radiofrequency ablation in the treatment of obstructive hypertrophic cardiomyopathy under the guidance of intracardiac ultrasound
Sponsors
Zhongshan Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Obstructive hypertrophic cardiomyopathy (LVOTG >= 50 mmHg on echocardiography, resting or stress state), with or without SAM sign; 2. Aged >= 18 years; 3. Accompanied by clinical symptoms (including fatigue, shortness of breath, exertional angina pectoris, amaurosis, syncope, etc. affecting life), insufficient drug treatment effect or intolerable adverse drug reactions; 4. Informed consent of patients and their families, the principle of voluntary participation, and the process of obtaining informed consent conforms to GCP regulations.
Exclusion criteria
Exclusion criteria: 1. There are surgical contraindications: including abnormal coagulation function, contraindications to anticoagulation, pregnant and lactating women; 2. Left ventricular ejection fraction < 40%; 3. Life expectancy < 12 months; 4. Patients who are allergic to anesthetic drugs and cannot tolerate surgery; 5. Combined with other heart diseases requiring surgical treatment; 6. The patient has poor compliance and cannot complete the test requirements; 7. There are patients who are considered unsuitable to participate in this study by other researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| left ventricular outflow tract gradient, LVOTG; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events; | — |
Countries
China
Contacts
Public ContactZhu Wenqing
Zhongshan Hospital Affiliated to Fudan University
Outcome results
None listed